Characterization of trypsinogens 1 and 2 in two human pancreatic adenocarcinoma cell lines; CFPAC‐1 and CAPAN‐1

Abstract

Proteins with trypsin-like immunoreactivity (first detected by a specific immunoenzymatic assay) were isolated from CAPAN-1 and CFPAC-1 cell culture-conditioned media by chromatography on an immunoadsorbent prepared with a polyclonal antibody directed against trypsin 1. The adsorbed proteins were devoid of free trypsin activity but trypsin activity was present after enterokinase activation demonstrating that the immunoreactive trypsin present in cell supernatants corresponds to trypsinogens. When characterised by Western blotting using a monoclonal antibody directed against human trypsin 1 two protein bands corresponding to trypsinogen 1 (23 kDa) and trypsinogen 2 (25 kDa) gave a positive reaction. These results demonstrate the presence of trypsinogens 1 and 2 in CAPAN-1 and CFPAC-1 cells and in their culture-conditioned media.

Ribonucleases expressed by human pancreatic adenocarcinoma cell lines

“…Trypsinogen mRNA was detected in Capan‐1, AsPc‐1, MDAPanc‐3 and MDAPanc‐28 cells at different levels. Trypsinogen expression seems to be somewhat correlated with the invasive or metastatic potential of the cell lines [44]. The expression of a mixture of ductal, acinar and islet cell products in human pancreatic adenocarcinoma was reported previously by Kim et al .…”

Molecular Cloning of the Oncofetal Isoform of the Human Pancreatic Bile Salt-dependent Lipase

“…Ductal phenotype marker such as carbonic anhydrase II was detected in some cell lines such as BxPC-3 but not in PANC-1 (36). Trypsinogens 1 and 2, which are markers for the acinar phenotype, were detected in CF-PAC-1 and CAPAN-1 cells but not in PANC-1 cells (37). In a previous study, we showed that human pancreatic tumoral cell lines BxPC-3 and SOJ-6 and human pancreatic adenocarcinoma tissue expressed a 46-kDa (p46) immunoform of BSDL, whereas the 100-kDa (p100) immunoform could not be detected in clarified cell extracts (22).…”

Serum trypsinogen-2 and trypsin-2-α1-antitrypsin complex in malignant and benign digestive-tract diseases. Preferential elevation in patients with cholangiocarcinomas

“…Because trypsinogen-2 and trypsin-2-AAT are better markers for pancreatitis than trypsinogen-1 Hedstriim et al, 1994), we wanted to evaluate their usefulness as markers for pancreatic cancer. Since tumor-associated trypsin-2 is expressed by various tumorcell lines (Koivunen et al, 1991;Miszczuk-Jamska et al, 1991) we also studied patients with other digestive-tract cancers. Patients with benign digestive-tract diseases were used as controls.…”